These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17688499)

  • 21. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size determination for testing equality in Poisson frequency data under an AB/BA crossover trial.
    Lui KJ
    Pharm Stat; 2013; 12(2):74-81. PubMed ID: 23364859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing approaches for overdispersion in poisson regression versus the generalized poisson model.
    Yang Z; Hardin JW; Addy CL; Vuong QH
    Biom J; 2007 Aug; 49(4):565-84. PubMed ID: 17638291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Confidence interval for statistical power using a sample variance estimate.
    Liu X
    Nurse Res; 2013; 21(1):40-6. PubMed ID: 24004431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sample size calculations for noninferiority trials with Poisson distributed count data.
    Stucke K; Kieser M
    Biom J; 2013 Mar; 55(2):203-16. PubMed ID: 23401289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motor unit number estimation--a Bayesian approach.
    Ridall PG; Pettitt AN; Henderson RD; McCombe PA
    Biometrics; 2006 Dec; 62(4):1235-50. PubMed ID: 17156299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?
    Salem F; Ogungbenro K; Vajjah P; Johnson TN; Aarons L; Rostami-Hodjegan A
    J Clin Pharmacol; 2014 Mar; 54(3):311-7. PubMed ID: 24122884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sample sizes based on exact unconditional tests for phase II clinical trials with historical controls.
    Chang MN; Shuster JJ; Kepner JL
    J Biopharm Stat; 2004 Feb; 14(1):189-200. PubMed ID: 15027508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simple method for calculating power based on a prior trial.
    Borm GF; Bloem BR; Munneke M; Teerenstra S
    J Clin Epidemiol; 2010 Sep; 63(9):992-7. PubMed ID: 20573484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power and sample size estimation for the Wilcoxon rank sum test with application to comparisons of C statistics from alternative prediction models.
    Rosner B; Glynn RJ
    Biometrics; 2009 Mar; 65(1):188-97. PubMed ID: 18510654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
    Cheng Y; Shen Y
    Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
    Nie L; Chu H; Cole SR
    Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    Biom J; 2007 Aug; 49(4):613-26. PubMed ID: 17634977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.